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many individuals with extensive atherosclerotic vascular
change (plaque formation in arterial walls) experience no
symptoms during life and die of other causes. One feature
that distinguishes atherosclerotic disease from atheroscle-
rotic change as a normal consequence of aging is the
occurrence of symptoms. Because atherosclerosis of the
coronary arteries and atherosclerosis of the cerebral arter-
ies underlie two of the three leading causes of death, there
is tremendous interest in predicting which individuals may
be at increased risk for progressive symptoms. One ques-
tion is whether there is a relationship between the site of
the presenting symptoms and progression of systemic ath-
erosclerosis. The three most frequently encountered
symptomatic areas are coronary heart disease (CHD),
lower-extremity disease (LED), and carotid artery disease
(cerebrovascular disease [CVD]).
Atherosclerosis is sufficiently common enough in
Western countries to blur the distinction between the dis-
ease process and the normal aging process. However,
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Purpose: There have been few studies of the natural history of peripheral arterial disease (PAD), and none have used
serial noninvasive laboratory examinations for the objective quantification of disease progression. The relationship
between the site of initial symptoms of PAD (lower-extremity disease [LED] vs cerebrovascular disease [CVD]) and the
site of subsequent symptomatic progression (LED vs CVD vs coronary heart disease [CHD]) has not been examined.
Methods: This is a long-term, blinded prospective clinical research study of the relationship of PAD progression to multiple
clinical, laboratory, and noninvasive vascular laboratory parameters. Patients with symptomatic LED, CVD, or both under-
went comprehensive risk-factor assessment and were seen every 6 months for follow-up examinations. In addition to his-
tory and physical examination, all subjects underwent serial noninvasive lower-extremity and carotid artery testing. The
relationship between the initial symptomatic site(s) and subsequent progression was examined by means of multivariate
proportional hazards analysis, which was adjusted for age, diabetes mellitus, hypertension, smoking, cholesterol, homo-
cysteine level, lowest initial ankle/brachial index (ABI), worst carotid stenosis, ABI progression, and carotid stenosis pro-
gression, because each of these factors was significantly associated with one or more aspects of progression.
Results: There were 397 study subjects (mean age, 66 years; 38% women) with a mean follow-up period of 48.5 months.
LED was initially present in 88% of subjects and CVD in 37% of subjects (both were present in 25% of subjects). There
were 78 deaths, 47 (60%) of which were caused by cardiovascular disease (18% mortality rate after 5 years by means of
life table). Progression of disease as documented by means of vascular laboratory findings occurred in 90% of subjects
by means of life table after 5 years (ABI progression, 31%; carotid stenosis progression, 40%). Symptomatic clinical pro-
gression of disease occurred in 52% of subjects by means of life table after 5 years (LED progression, 22%; CVD pro-
gression, 23%; CHD progression, 31%). By means of multivariate analysis, no significant relationship was found
between the site of initial symptoms of PAD and the site(s) of subsequent symptomatic clinical progression (LED vs
CVD vs CHD; P = not significant for all hazard ratios).
Conclusion: Patients with symptomatic PAD experience symptoms of ongoing LED, CVD, and CHD with a frequency
that is not influenced by the site(s) of their original symptoms. The hypothesis that lesions and resulting symptoms of
systemic atherosclerosis occur at various anatomic sites as a matter of random chance should be tested with other stud-
ies. (J Vasc Surg 2002;35:38-47.)
Multiple studies have focused on increased morbid-
ity/mortality in patients with peripheral arterial disease
(PAD).1-3 These studies have fostered an increasing inter-
est in the characterization of the extent and prognosis of
PAD, both in populations and in individuals. Patients with
symptomatic PAD are especially suited for prospective lon-
gitudinal studies because of the ease with which progres-
sion of atherosclerotic lesions can be repeatedly assessed
by using noninvasive testing, independent of symptoms
and without risk or discomfort.
A large body of literature has developed around non-
invasive testing of PAD. The ability of noninvasive testing
to quantitatively document disease progression that corre-
lates directly with increasing severity and/or frequency of
symptoms in the vascular bed being tested is well known.
A number of studies have also documented a relationship
between the severity of disease detected by means of non-
invasive testing and the subsequent prognosis, suggesting
that the results of noninvasive testing of peripheral arter-
ies may also be quantitatively related to the severity of the
systemic atherosclerotic process.4-6
The Homocysteine and Progression of Atherosclerosis
Study (HPAS) is a clinical research study that began in
1991 to examine the relationship between progression of
symptomatic PAD, plasma homocysteine levels, and vita-
min treatment. The results of HPAS on the influence of
homocysteine levels on progression of disease have already
been reported.7 HPAS includes comprehensive risk factor
assessment and routine longitudinal clinical and vascular
laboratory follow-up, which makes the HPAS subject pop-
ulation ideal for testing the influence of various risk factors
on atherosclerotic disease progression. An analysis of the
HPAS data conducted to determine whether the site(s) of
presenting symptoms of PAD (CVD vs LED) has/have
independent prognostic implications about the site(s) of
subsequent progression of systemic atherosclerosis forms
the basis for this report.
METHODS
Patient Selection. HPAS is being conducted at
Oregon Health and Sciences University by using the facil-
ities of the Division of Vascular Surgery and the General
Clinical Research Center. Consecutive patients seen in the
vascular surgery clinics who were undergoing long-term
follow-up and had symptomatic PAD (claudication, limb-
threatening ischemia, transient cerebral ischemia, stroke)
and vascular laboratory evidence of disease at the sympto-
matic site (ankle brachial pressure index [ABI] < 0.90 or
carotid stenosis > 16% diameter reduction) were recruited
for the study. To be eligible for the study, the patients had
to have at least one carotid artery or at least one leg that
had not undergone surgery, because the study was
intended to examine the progression of atherosclerosis in
unoperated vessels rather than postoperative recurrent dis-
ease. Patients with unstable disease (limb-threatening
ischemia, repeated transient ischemic attacks) were not
enrolled until treatment had returned them to a stable
symptomatic status. Patients were also enrolled into the
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study when they had a history of PAD symptoms that had
been eliminated by means of revascularization with
surgery or angioplasty, when the symptoms had been
accompanied by appropriate vascular laboratory findings
before the revascularization.
Human subjects protection. HPAS is fully approved
by the Institutional Review Board of Oregon Health and
Sciences University and by the Advisory Committee of the
Oregon Health and Sciences University General Clinical
Research Center. All subjects gave informed consent for
participation.
Initial evaluation. All subjects underwent a stan-
dardized medical history and physical examination, a com-
prehensive laboratory examination (Table I), and vascular
laboratory testing of the lower extremities and carotid
arteries. The lower-extremity testing included segmental
limb pressures and ankle blood pressure response to tread-
mill walking.8 Carotid artery testing was conducted with
duplex ultrasound scanning, with assignment of each
carotid artery to one of six categories as dictated by the
University of Washington criteria (category A, 0% stenosis;
category B, 1%-16% stenosis; category C, 17%-49% steno-
sis; category D, 50%-79% stenosis; category D+, 80%-99%
stenosis; category E, occluded).9
Follow-up. Subjects were seen by one of the investi-
gators every 6 months. An interval history and a physical
examination were performed, and the vascular laboratory
testing was repeated.
Treatment. Patients underwent standardized man-
agement of PAD. Nonoperative management included
daily aspirin (325 mg/day), counseling about smoking
cessation, and a recommendation for daily walking exer-
cise. The counseling and recommendation for exercise
Fig 1. Symptoms of peripheral arterial disease present at the time
of entry into the study. LED, Lower-extremity disease; CVD,
cerebrovascular disease.
were repeated at each follow-up visit. Lipid-lowering
treatment was recommended, as per American Heart
Association guidelines (41% of subjects).10
HPAS includes a randomized trial of folate (4
mg/day) versus a placebo, into which subjects began to be
randomized in 1997. Some of the data in this analysis
include subjects in both randomized groups. No differ-
ences in disease progression between the randomized
groups was shown by means of a blinded analysis of the
study results performed in June 2001. Therefore, data
from the postrandomization phase of HPAS are included
in this analysis.
Revascularization for lower-extremity ischemia was
recommended for disabling claudication or for limb-
threatening ischemia and was performed by the investiga-
tors according to principals published earlier.11 Carotid
endarterectomy was recommended for symptomatic
stenosis with more than 70% diameter reduction for
patients who met other published eligibility criteria for the
North American Symptomatic Carotid Endarterectomy
Trial12 or for the progression of asymptomatic stenosis to
more than 60% diameter reduction for patients who met
other published criteria for entry into the Asymptomatic
Carotid Atherosclerosis Study.13
Definition of disease progression. The progression
of disease in HPAS includes both lesion-defined parame-
ters (vascular laboratory) and event-defined parameters
(clinical events). The clinical events indicating sympto-
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matic progression of CHD, CVD, and LED are listed in
Table II. Nonfatal progression as determined by means of
symptoms was documented by conducting a patient inter-
view at the time of regularly scheduled follow-up visits, by
hospital discharge diagnoses, and by communication with
primary care physicians. Death from cardiovascular disease
and death from any cause were also considered to be end
points. The cause of death was determined from autopsy
reports when available or from hospital discharge sum-
maries or death certificates. Vascular laboratory progres-
sion of LED was defined as a decrease in ABI of more than
–0.15. Vascular laboratory progression of CVD was
defined as an increase in carotid stenosis of at least one cat-
egory.
Blinding. HPAS is a blinded study. All study data are
kept in a dedicated database, with patients identified by
means of a number only. Investigators are blinded to
homocysteine levels and to randomization status. The
technicians who performed the vascular laboratory testing
are blinded to the results of the patients’ earlier tests and
to clinical events.
Data analysis. The clinical and vascular laboratory
indicators of progression listed in Table II and under the
aforementioned “Progression of Disease” were tabulated
by using the life table method. Recurrent disease in areas
of earlier vascular reconstructions were not included as
progression events. Factors from a patient’s baseline exam-
ination that were related to the various clinical and vascu-
lar laboratory indicators of progression were determined
by means of the log-rank method. The influence of the
site(s) of symptoms at the time of study entry (CVD vs
LED) on the site(s) of clinical and vascular laboratory pro-
gression of disease was examined in a multivariate Cox
proportional hazards model for censored data, with time
to the various end points being the dependent variable.
The model was originally constituted by using all relevant
study data as independent variables, and then, in sequen-
tial fashion, the model was refined to include only those
independent variables that had a significant influence on
the time to the various end points. The analyses were all
Table I. Laboratory testing obtained for the
Homocysteine and Progression of Atherosclerosis Study
Hematology
Complete blood count
Platelet count
Chemistry
Electrolyte level
Creatinine level
Bilirubin level
Total protein level
Albumin level
Urea nitrogen level
Glucose level
Lipids
Cholesterol level
Low-density lipoprotein cholesterol level
High-density lipoprotein cholesterol level
Lipoprotein (a) level
Triglyceride level
Coagulation
Prothrombin time
Partial thromboplastin time
Antithrombin III
Protein C
Protein S
Anticardiolipin antibodies
Homocysteine and vitamins
Homocysteine
Thermolabile methylenetetrahydrofolate reductase
Folate
B6
B12
Table II. Clinical end points for disease progression
Lower extremity disease
Major—Amputation
Minor—Worse ischemia*
Surgery
Angioplasty/stenting
Cerebrovascular disease
Major—Stroke
Minor—transient ischemic attack
Carotid endarterctomy
Heart disease
Major—Myocardial infarction
Minor—Angioplasty/stenting
Coronary artery bypass grafting
Unstable angina
Congestive heart failure
Arrhythmia
*Worsening claudication or the development of rest pain, ulcer, or gangrene.
adjusted for the influence of the number of arteries avail-
able for assessment, because various subjects had from one
to four arteries available for vascular laboratory assessment
of progression.
The SAS and JMP statistical software packages for per-
sonal computers (SAS Institute, Cary, NC) were used for
all data analyses.
RESULTS
Subjects. From August 1991 through April 2001,
462 patients consented to enter the study. Sixty-five sub-
jects did not return for at least one 6-month follow-up
visit (38 of the subjects [58%] with no follow-up visits
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were recruited within the past 6 months, and 27 of the
subjects [42%] with no follow-up visits did not return after
the initial visit) and are excluded from this analysis. The
397 subjects (151 women, 38%) who returned for at least
one 6-month follow-up visit constitute the current study
group. Symptoms of LED were present in 351 subjects
(88%) and symptoms of CVD were present in 146 subjects
(37%), whereas 100 subjects (25%) had both LED and
CVD (Fig 1). Factors related to atherosclerosis present at
the initial study visit are shown in Table III. Significantly
more subjects with LED were current smokers. As
expected, earlier interventions for LED and CVD were
significantly more frequent (P < .001 for LED and CVD)
Fig 2. Survival rate for all subjects by means of life table.
Table III. Selected baseline demographics of study subjects grouped according to clinical symptoms at study entry
Symptoms at study entry
All subjects LED symptoms CVD symptoms Both LED and CVD
Parameter (n = 397) only (n = 251) only (n = 46) symptoms (n = 100) P value*
Age (mean ± SD; years) 65.9 ± 8.8 65.7 ± 9.2 66.4 ± 7.9 66.6 ± 8.1 .67†
Women 151 (38%) 106 (42%) 17 (37%) 28 (28%) .046‡
Diabetes mellitus 85 (21%) 50 (20%) 8 (17%) 27 (27%) .27‡
Heart disease 192 (48%) 112 (45%) 23 (50%) 57 (57%) .11‡
Hypertension 244 (61%) 150 (60%) 25 (54%) 69 (69%) .16‡
Current tobacco smoking 130 (33%) 87 (35%) 6 (13%) 37 (37%) .01‡
Fasting serum cholesterol level 217 ± 47 217 ± 47 218 ± 45 216 ± 50 .98†
(mean ± SD; mg/dL)
Plasma homocysteine level 14.1 ± 6.9 14.3 ± 7.4 12.1 ± 4.8 14.6 ± 6.6 .12†
(mean ± SD; nmol/mL)
Earlier intervention for LED 154 (39%) 107 (43%) 3 (7%) 44 (44%) <.0001‡
Earlier intervention for CVD 91 (23%) 2 (<1%) 34 (74%) 55 (55%) <.0001‡
Earlier intervention for CHD 82 (21%) 43 (17%) 15 (33%) 24 (24%) .04‡
*Probability, by means of the indicated test, that the “symptoms at study entry” categories differ from one another.
†Analysis of variance.
‡Chi-square.
LED, Lower-extremity disease; CVD, cerebrovascular disease; CHD, coronary heart disease.
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in subjects with these symptoms. Earlier intervention for
CHD was more frequent in subjects with CVD (P = .04).
By means of vascular laboratory criteria, LED was
found to be present in 75% of all subjects and ranged in
prevalence from 84% of subjects who had LED symptoms
only to 13% of subjects who had CVD symptoms only.
Fewer than 100% of subjects with each category of symp-
toms had corresponding vascular laboratory abnormalities
because subjects whose symptomatic vascular laboratory
abnormalities had been corrected with revascularization
were included. The mean lowest ABI for all subjects was
0.75, and the ABI ranged from 0.71 in subjects who had
LED symptoms only to 1.00 in subjects who had CVD
symptoms only. The median worst carotid stenosis was a
17% to 49% diameter reduction in all subjects, and it
ranged from a 1% to 16% diameter reduction in subjects
who had LED only to a 17% to 49% diameter reduction in
subjects who had CVD symptoms only. As expected, the
differences in frequency and severity of vascular laboratory
evidence of LED and CVD between the subjects with
symptoms of LED and CVD were all statistically signifi-
cant (the P value by means of analysis of variance for con-
tinuous variables or by means of chi-square for categorical
variables ranged from .013 to < .0001 for various com-
parisons; Table IV).
Follow-up. The mean follow-up period for all sub-
jects was 48.5 months (range, 1-114 months; SD, 33.0
months). 
Survival. Seventy-eight subjects (20%) died during
follow-up, at a mean interval of 38 months (range, 1-96
months; SD, 24.5 months). Forty-seven deaths (60%)
were caused by cardiovascular disease (12% cardiovascular
mortality). The all-cause mortality rate and the cardiovas-
cular mortality rate determined by means of life table are
shown in Fig 2. Death was the single most frequent clini-
cal event that occurred in these subjects. The second most
frequent single event was surgery for LED (16% by means
of life table after 5 years; Table V).
Clinical progression of disease. During follow-up,
78 subjects (20%) had clinical progression of LED, and
71 subjects (18%) had clinical progression of CVD.
Progression of symptomatic CHD (101 subjects [25%])
was the most frequent category of clinical disease pro-
gression. These percentages and the overlap between the
various groups are shown in Fig 3. By means of life table,
clinical progression of disease was found to have occurred
in at least one symptomatic category in 52% of subjects
after 5 years. Progression to one or more major clinical
events (stroke, myocardial infarction, amputation, or
death from cardiovascular disease) occurred in 25% of
subjects after 5 years. Of the major end points, death
from cardiovascular disease (12% by means of life table
after 5 years) was the most frequent, and amputation (3%
by life table after 5 years) was the least frequent. Life table
values for clinical progression of disease in these cate-
gories and in the various subcategories of symptoms are
shown in Table V.
Progression of disease by vascular laboratory.
Progression of disease as assessed by means of vascular lab-
oratory testing occurred more than twice as frequently as
progression of disease as assessed by means of clinical
symptoms. ABI progression occurred in 117 subjects
(30%). Carotid stenosis progression occurred in 154 sub-
jects (39%). Vascular laboratory progression of disease and
the overlap between the two groups is shown in Fig 4. By
means of life table after 5 years of follow-up, progression
of disease as assessed by means of at least one vascular lab-
oratory test modality had occurred in 90% of subjects (Fig
5). Life table values for progression of disease in these cat-
egories is shown in Table VI.
Fig 4. Progression of disease as assessed by means of a vascular
laboratory during follow-up.
Fig 3. Symptomatic clinical progression of disease during follow-up.
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Factors associated with clinical progression of
disease. The were no differences in clinical outcome
resulting from sex (data not shown). As expected, age,
diabetes mellitus, hypertension, cholesterol level, smok-
ing, and homocysteine level were all shown by means of
multivariate Cox proportional hazards analysis to be sig-
nificantly associated with one or more aspects of disease
progression, as assessed by means of clinical symptoms,
death, or both (data not shown). Also as expected, ABI
progression significantly increased the risk of progression
of symptomatic LED (hazard ratio, 2.98; 95% CI, 1.79-
5.07; P < .00001), and carotid stenosis progression sig-
nificantly increased the risk of progression of
symptomatic CVD (hazard ratio, 1.84; 95% CI, 1.10-
3.14; P = .02). Baseline worst carotid stenosis was signif-
icantly associated with subsequent death (hazard ratio,
1.37; 95% CI, 1.07-1.74; P = .01). The inverse associa-
tion of baseline ABI with death was as expected, but was
of marginal significance (hazard ratio, 0.39; 95% CI,
0.13-1.27; P = .11). Because of these associations, the
multivariate analyses of the effect of initial clinical symp-
toms on clinical progression of disease were all adjusted
for age, diabetes mellitus, hypertension, cholesterol level,
smoking, homocysteine level, lowest initial ABI, worst
initial carotid stenosis, LED, CVD, and CHD at study
entry and for ABI progression and carotid stenosis pro-
gression during follow-up.
Relationship of site of initial clinical symptoms to
site of clinical progression of disease. Within the limits
of power imposed by the number of subjects in this study,
there were no significant independent differences in the
site(s) of clinical progression of CVD, LED, or CHD, or
in survival, according to the site(s) of PAD symptoms at
study entry (CVD vs LED). The hazard ratios determined
Fig 5. Vascular laboratory progression of disease by means of life table.
Table IV. Baseline vascular laboratory findings of study subjects grouped according to clinical symptoms at study entry
Symptoms at study entry
All subjects LED symptoms CVD symptoms Both LED and CVD
Parameter (n = 397) only (n = 251) only (n = 46) symptoms (n = 100) P value*
ABI ≤ 0.90 289 (75%) 212 (84%) 6 (13%) 80 (80%) <.0001†
Carotid stenosis > 16% 209 (53%) 118 (47%) 28 (61%) 63 (63%) .013†
Carotid stenosis > 16% and ABI ≤ 0.90 159 (40%) 104 (41%) 4 (9%) 51 (51%) <.0001†
Mean lowest ABI (± SD) 0.75 ± 0.24 0.71 ± 0.22 1.02 ± 0.21 0.71 ± 0.20 <.0001‡
Median worst carotid stenosis 17%-49% 1%-16% 17%-49% 17%-49% .002‡
*Probability by means of the indicated test that the “symptoms at study entry categories” differ from one another.
†Chi-square.
‡Analysis of variance.
LED, Lower-extremity disease; CVD, cerebrovascular disease; CHD, coronary heart disease; ABI, ankle/brachial index
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by means of the multivariate proportional hazards analysis
for each major category of clinical progression (CVD,
LED, and CHD) and for the major clinical end points of
myocardial infarction, stroke, amputation, and death from
cardiovascular disease according to the type of symptoms
present at study entry are shown in Table VII. Amputation
was required in only six subjects; it was the least frequent
clinical event and did not occur with sufficient frequency
to allow calculation of reliable hazard ratios (Table VII).
DISCUSSION
This analysis of the HPAS data confirmed the fre-
quently reported increased mortality rate (18% by life
table after 5 years) occurring in patients with symptomatic
PAD (the anticipated 5-year mortality rate for the US gen-
eral population aged 67 years is 9%).14 Earlier studies of
patients with PAD have confirmed that mortality is
directly related to the severity of PAD, whether assessed by
means of severity of symptoms or by means of vascular lab-
oratory findings.1-6,15 HPAS has used an inclusive defini-
tion of progression of atherosclerotic disease, as described
in detail in the Methods section, which includes both
lesion-defined (vascular laboratory) and event-defined
(clinical events) parameters, to maximize study power.
Nonfatal progression of disease as documented in the vas-
cular laboratory was more than twice as frequent as pro-
gression as documented by means of clinical symptoms
(Tables V and VI). The most frequent symptomatic site of
clinical progression was CHD, followed equally by LED
and CVD. The severity of initial disease as documented by
means of vascular laboratory findings (mean lowest ABI,
0.75; median worst carotid stenosis, 17%-49% diameter
reduction) was moderate. This is partly because the entry
criteria for the study required that patients have stable
symptomatic PAD (active symptoms of limb-threatening
ischemia, transient ischemic attack, and/or stroke were
excluded). Earlier studies that are appropriate for compar-
ison are, therefore, those that included patients with clau-
dication, rather than more severely affected patients with
critical limb ischemia. The 5-year mortality rate reported
by several earlier studies of patients with claudication
ranged from 25% to 45%.16-19
Table VI. Vascular laboratory progression by means of life table
End point 1 year 3 years 5 years
ABI progression* 0.3% 19% 37%
Carotid stenosis progression† 13% 35% 48%
Either ABI or carotid stenosis progression 35% 74% 90%
*Decrease in ABI of ≥0.15.
†Progression of one category of stenosis on the basis of University of Washington criteria.
ABI, Ankle/brachial index.
Table V. Occurrence of clinical progression end points by means of life table
End point 1 year 3 years 5 years
LED
Amputation 0 0.4% 3%
Worsening ischemia* 0.8% 9% 14%
Surgery 1% 10% 16%
Angioplasty/stenting 0 0.6% 2%
Any LED end point 1% 14% 22%
CVD
Stroke 1% 4% 9%
TIA 0 4% 6%
Carotid surgery 0 7% 12%
Any CVD end point 0.8% 13% 23%
Heart disease
Myocardial infarction 0.3% 4% 9%
Unstable angina 0 6% 10%
Bypass grafting surgery 0.5% 6% 6%
Angioplasty/stenting 0 3% 4%
Congestive heart failure 0 4% 8%
Arrhythmia 0 3% 7%
Any heart disease end point 1% 16% 31%
LED or CVD or heart disease 3% 37% 52%
Any major end point† 1.5% 12% 25%
*Worsening claudication or the development of rest pain, ulcer, or gangrene.
†Includes myocardial infarction, stroke, amputation, and death from cardiovascular disease.
LED, Lower-extremity disease; CVD, cerebrovascular disease; TIA, transient ischemic attack.
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As with all other recent studies of PAD, HPAS is not a
true natural history study. All subjects participating in HPAS
have been given continuous treatment for PAD, including
daily aspirin, cholesterol-lowering medication when appropri-
ate, and management of LED, CVD, and CHD by means of
standardized protocol. Given the positive effect of participa-
tion in a clinical research protocol and the uniformly applied
treatment, decreased mortality for HPAS subjects when com-
pared with subjects of other observational studies of PAD is
not surprising. However, some parameters of progression
have occurred with greater frequency than might be expected
from recently reported studies. The 9% life table occurrence
of stroke, for instance, is similar to that in the medically
treated arm of the Asymptomatic Carotid Atherosclerosis
Study, despite carotid endarterectomy being performed in the
HPAS population as per the indications of this study. The
Asymptomatic Carotid Atherosclerosis Study population was
carefully screened for low overall cardiovascular risk and is not
an equivalent population to the HPAS study population.
There is near universal recognition that symptomatic
atherosclerosis is a systemic disease process. Despite this,
current practice frequently regards patients with differing
symptomatic manifestations of atherosclerosis as if they
were suffering from distinctly different diseases. This prac-
tice is exemplified by accepted nomenclature that refers to
patients with “coronary artery disease” versus patients
with “peripheral arterial disease” or “carotid artery dis-
ease,” etc.20 Similarly, clinical research trials intended to
study atherosclerotic disease are frequently limited to
patients with symptomatic manifestations in a single, nar-
rowly defined area and evaluate only outcomes in that area
(eg, occurrence of myocardial infarction in patients pre-
senting with angina pectoris). A legitimate question is
whether patients with different symptomatic manifesta-
tions of atherosclerosis have differing prognoses depend-
ing on the site of their initial symptoms.
Despite decades of research into the most common dis-
ease process affecting Western populations, the cause(s) of
atherosclerosis remain(s) unknown. What is well known is
that both the presence and progression of atherosclerosis
are significantly affected by multiple risk factors, including,
but not limited to, age, diabetes mellitus, smoking tobacco,
hypertension, and cholesterol level, and these relationships
were confirmed in this study. After adjusting for these
important factors, this study does not support the hypoth-
esis that there is any independent relationship between the
site of presenting or earlier symptoms of atherosclerosis and
the rate of occurrence/site of subsequent symptoms, nor is
there an independent relationship between presenting or
earlier symptoms of atherosclerosis and survival. Rather,
these results appear to support the hypothesis that patients
with symptomatic atherosclerosis experience symptoms in
lower-extremity arterial, carotid, and coronary areas as a
matter of random chance.(Table VII). It is tempting to con-
clude that any supposed differences between patients on the
basis of symptoms results more from the division of physi-
cians into different medical specialities than from any true
difference in patients or in the underlying nature of the ath-
erosclerotic disease process.
The results of this study must be interpreted with
appropriate caution. The entry criteria were limited to
patients with symptomatic LED, CVD, or both. In the
absence of further information, the conclusions must only
be applied to such patients. Similarly, the study was limited
in size to 400 subjects who were observed for a mean of
just more than 4 years. A larger/longer study would have
greater power to detect small differences in prognosis.
We conclude that patients with symptomatic PAD
experience symptoms of ongoing LED, CVD, and CHD
with a frequency that is not influenced by the site(s) of
their presenting symptoms. The hypothesis that lesions
and resulting symptoms of systemic atherosclerosis occur
Table VII. Hazard ratios (with 95% confidence intervals) for clinical progression of disease according to symptoms
present at study entry*
Symptoms at study entry
Clinical progression during follow-up LED CVD
LED† 2.48 (0.72-11.50) 0.83 (0.40-1.60)
CVD‡ 1.26 (0.51-3.32) 0.84 (0.39-1.69)
Heart disease§ 0.95 (0.43-2.20) 1.08 (0.60-1.87)
Cardiovascular death|| 0.98 (0.30-3.55) 1.00 (0.42-2.20)
Any death 0.65 (0.27-1.64) 1.13 (0.58-2.12)
Amputation¶ –– ––
Stroke 1.43 (0.29-8.17) 0.78 (0.23-2.20)
Myocardial infarction 2.28 (0.49-16.53) 1.13 (0.40-2.91)
*Values obtained by means of multivariate Cox proportional hazards analysis adjusted for age, hypertension, diabetes mellitus, smoking history, cholesterol
level, number of lower extreity and carotid arteries followed per patient, and heart disease, cerebrovascular disease, lower-extremity disease, lowest ABI, and
carotid stenosis at study entry (P = not significant for all relationships).
†Worsening claudication, rest pain, ulcer, or gangrene, need for revascularization, or need for major amputation.
‡Stroke, transient ischemic attack, or need for carotid surgery.
§Unstable angina, myocardial infarction, congestive heart failure, arrhythmia, or need for coronary artery bypass grafting surgery, angioplasty, and stenting.
||Death due to cerebrovascular, lower extremity, or cardiovascular cause.
¶Too few to analyze by means of Cox proportional hazards analysis.
LED, Lower-extremity disease; CVD, cerebrovascular disease.
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at various anatomical sites as a matter of random chance
should be tested by other studies.
REFERENCES
1. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and
cardiovascular disease events in symptomatic and asymptomatic
peripheral arterial disease in the general population. Int J Epidemiol
1996;25:1172-81.
2. Dormandy JA, Murray GD. The fate of the claudicant—a prospective
study of 1969 claudicants. Eur J Vas Surg 1991;5:131-3.
3. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of
10 years in patients with peripheral arterial disease. N Engl J Med
1992;326:381-6.
4. Vogt MT, Cauley, Newman AB, et al. Decreased ankle/arm blood
pressure index and mortality in elderly women. J Am Med Assoc
1993;270:465-9.
5. Newman AB, Sutton-Tyrell K, Vogt MT, Kuller LH. Morbidity and
mortality in hypertensive adults with low ankle-arm blood pressure
index. J Am Med Assoc 1993;270:487-9.
6. McDermott MM, Feinglass J, Slavensky R, Pearce WH. The ankle-
brachial index as a predictor of survival in patients with peripheral vas-
cular disease. J Gen Intern Med 1994;9:445-9.
7. Taylor LM Jr, Moneta GL, Sexton GJ, et al. Prospective study of the
relationship between plasma homocysteine and progression of symp-
tomatic peripheral arterial disease. J Vasc Surg 1999;29:8-21.
8. Baur GM, Zupan TL, Holmgren-Gates K, Porter JM. Blood flow in
the common femoral artery. Am J Surg 1983;145:585-8.
9. Strandness DE Jr. Extracranial arterial disease. In: Strandness DE Jr,
editor. Duplex scanning in vascular disorders. 2nd ed. New York:
Raven Press; 1993. p. 113-58.
10. Expert panel on detection, evaluation, and treatment of high blood
cholesterol in adults. Summary of the second report of the national
cholesterol education program (NCEP) expert panel on detection
evaluation, and treatment of high blood cholesterol in adults (adult
treatment panel). JAMA 1993;269:3015-23.
11. Yeager RA, Taylor LM Jr, Porter JM. The present status of infrain-
guinal arterial reconstructive surgery for chronic lower extremity
ischemia. Curr Prob Surg 1991;28:125-39.
12. North American Symptomatic Carotid Endarterectomy (NASCET)
Steering Committee. North American Symptomatic Carotid
Endarterectomy Trial: methods, patient characteristics and progress.
Stroke 1991;22:711-20.
13. Asymptomatic Carotid Atherosclerosis Study Group. Study design for
randomized prospective trial of carotid endarterectomy for asympto-
matic atherosclerosis. Stroke 1989;20:844-9.
14. US Government. National vital statistics reports 2000;48:1-105.
15. Taylor LM Jr, Moneta GL, Porter JM. Natural history and nonoper-
ative treatment of chronic lower extremity ischemia. In: Rutherford
RB, editor. Vascular surgery. 5th ed. Philadelphia: WB Saunders;
2000. p. 928.
16. Bloor K. Natural history of arteriosclerosis of the lower extremities.
Ann R Coll Surg Engl 1961;28:36.
17. Kallero KS. Mortality and morbidity in patients with intermittent
claudication as defined by venous occlusion plethysmography: a ten
year follow-up. J Chronic Dis 1981;34:455.
18. Hertzer NR. Fatal myocardial infarction following lower extremity
revascularization: two hundred and seventy-three patients followed six
to eleven post-operative years. Ann Surg 1981;193:492.
19. Szilagyi DE, Elliott JP, Smith RF, et al. A thirty-year survey of the
reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc
Surg 1986;3:421.
20. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery dis-
ease, peripheral arterial disease, and atherothrombotic brain infarction
in men and women 62 years of age. Am J Cardiol 1994;74:64-5.
Submitted Jun 18, 2001; accepted Sep 6, 2001.
Dr Elliott L. Chaikof (Atlanta, Ga). Nicoloff and colleagues
from Oregon have followed some 400 patients with symptomatic
peripheral vascular disease since 1991 as part of their ongoing
homocysteine and progression of atherosclerosis study. It is note-
worthy that this is one of the few NIH-sponsored clinical trials
directed by vascular surgeons that has focused at understanding
the causes and long-term implications of a disease that defines our
profession. They should be commended for their efforts.
The Oregon group postulated that the prognostic implica-
tions may be quite different for those patients who initially present
with symptomatic cerebrovascular disease compared to those pre-
senting with symptoms of lower extremity disease. Their results do
not support this hypothesis but must be viewed with some caution
since their sample size is quite small. Perhaps the most striking
observation of their analysis is that progression of disease, by vas-
cular laboratory criteria, occurred in 90% of patients over 5 years.
This progression ensued despite the management of all patients
under a standardized protocol lipid lowering therapy and aspirin
consistent with current standards of care. This observation may
well raise a somewhat nihilistic presumption that with respect to
atherosclerosis there is a point of no return. Once we see the
symptomatic patient as vascular surgeons, there is little to do but
manage their downward spiral. I, for one, refuse to accept this
state of affairs and believe that the Oregon study poses a challenge
to all of us. We can and must be able to do better.
I have three questions for the authors.
A statistically significant difference in smoking history was
observed between patients with symptomatic lower extremity dis-
ease and those with cerebrovascular disease. Could this have
biased the results of your study?
Second, progression of disease by vascular laboratory criteria
did not occur in 10% of patients. Were these patients also free of
clinical progression?
And finally, were there any unique features that could be
identified for those patients who did not demonstrate progressive
disease? 
Dr Alexander D. Nicoloff Yes, I think perhaps it may have.
Fewer patients with only carotid artery disease at study entry were
current smokers, and they had less lower extremity disease pro-
gression. This fact influenced those patients’ progression of over-
all disease.
The second question you asked was regarding the 10% of
patients did not have progression of vascular lab and whether they
were free of clinical progression. Yes, some of them had clinical
progression. 
There was nothing of significance with regard to your
third question. The risk factors in these groups varied, but
again, the numbers in these subgroups were too small to draw
conclusions.
Dr G. Patrick Clagett (Dallas, Tex). In your abstract, you
identified elevated homocysteine as being a risk factor for pro-
gression of peripheral vascular disease. Is there hard evidence that
lowering that with treatment will prevent that progression, either
from your group or others?
Dr Nicoloff. Yes, we did have an original paper a couple years
ago that showed the relationship of homocysteine with progres-
sion of disease. However, we have not shown, and I don’t believe
it’s been shown by others, that treatment of elevated homocys-
teine prevents progression at this point. However, we are exam-
ining this question with this study. 
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Dr Clagett. Do you treat it?
Dr Nicoloff. In this study we randomized patients to vitamin
therapy with folate, and these data are yet to be presented.
Dr William C. Krupski (Denver, Colo). What was the corre-
lation with cigarette smoking and progression of disease? And did
you do anything in this population to try and decrease the inci-
dence of smoking?
Dr Nicoloff. Smoking was a risk factor for progression of dis-
ease in both groups. We address tobacco addiction by actively
encouraging patients to quit smoking at every encounter with
them. We also occasionally prescribe the standard patches and
medications as indicated.
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